The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb; Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Jianjun Gao
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca; crispr therapeutics; Jounce Therapeutics; Nektar; Pfizer; Polaris
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Ying Yuan
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Midas Medical Technologies; SERVIER; Starpax Medical; Vertex
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Sangeeta Goswami
No Relationships to Disclose
 
Amado J. Zurita
Honoraria - Exelixis; Janssen Oncology; Pfizer
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Matthew T Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Paul G. Corn
Research Funding - Janssen Oncology (Inst)
 
Claudia Ramos
Employment - Mirati Therapeutics
 
Xiaohong Yan
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Curtis Chin
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Hirak Der-Torossian
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Nektar; Neoleukin Therapeutics; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology